The drug Gleevec binds to and inactivates BCR-ABL, a mutant kinase that causes chronic myeloid leukemia.
Mutations in the BCR-ABL gene can cause resistance to Gleevec, but another drug, dasatinib, can be used instead.
Understanding that cancer is caused by mutations in genes that regulate cell proliferation has led to the development of targeted drug therapies.
A 3D model of BCR-ABL, an unregulated kinase that causes cancer.
A 3D model of adenosine triphosphate, or ATP.
A 3D model of imatinib (Gleevec), a drug that mimics ATP and inhibits BCR-ABL.
A 3D model of dasatinib, a drug that can inhibit BCR-ABL and Gleevec-resistant BCR-ABL.